𝐌𝐀𝐑𝐈𝐀𝐍𝐍𝐄 𝐕𝐎𝐆𝐒𝐄𝐍
@mariannevogsen.bsky.social
Kræftlæge med særlig affektion for brystkræft, formidling og en god dialog om lidt af hvert
📍Odense Universitetshospital, Danmark
📍Odense Universitetshospital, Danmark
Virkelig glad og sprængfyldt af fornyet forskningsenergi🔋 efter jeg idag modtog en bevilling fra Danmarks Fri Forskningsfond til fortsat klinisk forskning i bedre diagnostik, opfølgning og behandling af #brystkræft 🙏🏼 #MONITOR #PREMIOCOLLAB
dff.dk/aktuelt/nyhe...
dff.dk/aktuelt/nyhe...
8,8 millioner kroner giver læger mulighed for at fordybe sig i forskning
Danmarks Frie Forskningsfond har netop uddelt 8,8 millioner kroner under virkemidlet ’Delestillinger’. Seks klinikere får dermed muligheden for at forske ved siden af deres arbejde i en klinisk stilli...
dff.dk
January 9, 2025 at 9:22 PM
Virkelig glad og sprængfyldt af fornyet forskningsenergi🔋 efter jeg idag modtog en bevilling fra Danmarks Fri Forskningsfond til fortsat klinisk forskning i bedre diagnostik, opfølgning og behandling af #brystkræft 🙏🏼 #MONITOR #PREMIOCOLLAB
dff.dk/aktuelt/nyhe...
dff.dk/aktuelt/nyhe...
Reposted by 𝐌𝐀𝐑𝐈𝐀𝐍𝐍𝐄 𝐕𝐎𝐆𝐒𝐄𝐍
Anthracyline in #bcsm
My favorite quote: "Owing to the relentless math of proportional risk reduction ... improvements achieved through these non-anthra treatment enhancements mean that any residual clinical benefits from anthra are becoming progressively narrower"
ascopubs.org/doi/full/10....
My favorite quote: "Owing to the relentless math of proportional risk reduction ... improvements achieved through these non-anthra treatment enhancements mean that any residual clinical benefits from anthra are becoming progressively narrower"
ascopubs.org/doi/full/10....
Anthracyclines in Early Breast Cancer: The Long Goodbye | Journal of Clinical Oncology
ascopubs.org
November 14, 2024 at 7:38 PM
Anthracyline in #bcsm
My favorite quote: "Owing to the relentless math of proportional risk reduction ... improvements achieved through these non-anthra treatment enhancements mean that any residual clinical benefits from anthra are becoming progressively narrower"
ascopubs.org/doi/full/10....
My favorite quote: "Owing to the relentless math of proportional risk reduction ... improvements achieved through these non-anthra treatment enhancements mean that any residual clinical benefits from anthra are becoming progressively narrower"
ascopubs.org/doi/full/10....
Reposted by 𝐌𝐀𝐑𝐈𝐀𝐍𝐍𝐄 𝐕𝐎𝐆𝐒𝐄𝐍
Only 3 weeks to #SABCS24, a meeting that promises to significantly impact the way we treat breast cancer. It will feature phase 3 data with novel SERDs, novel ADCs, immunotherapy, ctDNA monitoring, important biomarker analyses & so much more. Here’s my top 10 abstracts list— see you in San Antonio!
November 17, 2024 at 8:01 PM
Only 3 weeks to #SABCS24, a meeting that promises to significantly impact the way we treat breast cancer. It will feature phase 3 data with novel SERDs, novel ADCs, immunotherapy, ctDNA monitoring, important biomarker analyses & so much more. Here’s my top 10 abstracts list— see you in San Antonio!
En krop med knogler, 5 scannere, 40 studier og 2 knalddygtige statistikere 📊 Det er opskriften på det systematiske review, som vi i lige har publiceret om scanninger til opsporing af knoglemetastaser fra #brystkræft. FDG-PET/CT og MR er de bedste og samtidig lige gode til formålet 👍🏼 Læs med her ⤵️
November 27, 2024 at 11:39 AM
En krop med knogler, 5 scannere, 40 studier og 2 knalddygtige statistikere 📊 Det er opskriften på det systematiske review, som vi i lige har publiceret om scanninger til opsporing af knoglemetastaser fra #brystkræft. FDG-PET/CT og MR er de bedste og samtidig lige gode til formålet 👍🏼 Læs med her ⤵️